The lawsuit that was supposed to define the next phase of the portal wars is over, but another power struggle is already taking shape across the country. Compass officially dropped its case against ...

Property brokerage Compass on Wednesday dropped its lawsuit against Zillow, ending a legal clash over how home listings can be marketed online. For the past few years, Compass — now the largest real ...

What does the Golden Compass do? If you've just started Act 2 and you're offered the Golden Compass as a helping hand to get you started, here's what you can expect from the item and why you should ...

Marc Santos is a Guides Staff Writer from the Philippines with a BA in Communication Arts and over six years of experience in writing gaming news and guides. He plays just about everything, from ...

Got an email about a Jilek v. Compass settlement? Payouts for millions in the US, including New Jersey, who used a vending machine in the last 11 years are being sent by check, PayPal, Venmo or Zelle ...

At the start of the month, Inman broke news regarding executive personnel changes at Anywhere. CEO Ryan Schneider and Chief Technology Officer Rudy Wolfs both exited the company, the publication ...

Rogers Healy is out of the real estate game. The venture capitalist and residential real estate mogul has merged his Dallas-based brokerage, Rogers Healy and Associates Real Estate, into New ...

Compass Coffee, the beleaguered D.C.-based chain, has a new owner. Elizabeth L. Gunn, a U.S. bankruptcy judge for the District of Columbia, approved the sale Thursday to London-based giant Caffè Nero, ...

Phase 3 clinical trial data has been a success. COMP360 is the first traditional psychedelic to consistently deliver a highly statistically significant outcome. Results included maintaining a ...

COMP360 shows rapid symptom improvement in depression study COMP360 may compete with J&J's Spravato if approved Compass plans FDA meeting for rolling submission Feb 17 (Reuters) - Compass Pathways ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the British biotech’s share price up 30% and teeing up talks about filing for ...